Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ceryvyn TherapeuticsCKDXF EV-to-OCF is -0.23 as of Aug. 12, 2026. The stock has 3 warning signs investors should review. Among 1,407 Biotechnology companies, Ceryvyn Therapeutics ranks worse than 70.43% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Ceryvyn Therapeutics's Enterprise Value is $36.91 Mil.
Ceryvyn Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 was $-158.64 Mil. Therefore, Ceryvyn Therapeutics's EV-to-OCF for today is -0.23.
The historical rank and industry rank for Ceryvyn Therapeutics's EV-to-OCF or its related term are showing as below:
CKDXF'
s EV-to-OCF Range Over the Past 10 Years
Min: -34.4 Med: -8.07 Max: 0.76
Current: -0.22
During the past 13 years, the highest EV-to-OCF of Ceryvyn Therapeutics was 0.76. The lowest was -34.40. And the median was -8.07.
CKDXF's EV-to-OCF is ranked worse than 70.43% of 1407
companies
in the Biotechnology industry
Industry Median: -3.54
vs CKDXF: -0.22
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ceryvyn Therapeutics's PE Ratio (TTM) for today is calculated as:
Ceryvyn Therapeutics's share price for today is $0.01.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ceryvyn Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was $-0.133.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ceryvyn Therapeutics EV-to-OCF Related Terms
Ceryvyn Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Ceryvyn Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ceryvyn Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ceryvyn Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ceryvyn Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Ceryvyn Therapeutics's EV-to-OCF falls into.
Ceryvyn Therapeutics's current Enterprise Value is $36.91 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ceryvyn Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 was $-158.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ceryvyn Therapeutics (CKDXF) has a EV-to-OCF of -0.23 as of Aug. 12, 2026. According to the industry distribution chart, Ceryvyn Therapeutics ranks #991 out of 1407 companies in the Biotechnology industry, placing it in the top 70.4%.
Is Ceryvyn Therapeutics' EV-to-OCF too high?
Ceryvyn Therapeutics' current EV-to-OCF is -0.23. Based on the distribution chart, Ceryvyn Therapeutics ranks #991 out of 1407 companies in the Biotechnology industry, which is below the industry midpoint.
How does Ceryvyn Therapeutics' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ceryvyn Therapeutics ranks #991 out of 1407 companies for EV-to-OCF. This places Ceryvyn Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Ceryvyn Therapeutics's current EV-to-OCF is -0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (CKDXF) has a current EV-to-OCF of -0.23. The current EV-to-OCF is -0.23. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Ceryvyn Therapeutics (CKDXF), the current EV-to-OCF is -0.23 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CKDXF has been successfully added to your 
